A prospective study that enrolled more than 10,000 women with hormone-receptor—positive, HER2-negative breast cancer has found that their response to a 21-gene test can identify patients who can avoid chemotherapy.
A prospective study that enrolled more than 10,000 women with hormone-receptor (HR)—positive, HER2-negative breast cancer has found that their response to a 21-gene test can identify patients who can avoid chemotherapy. Published in the New England Journal of Medicine, the trial found that in women who scored 10 or lower on the test and received standard hormone therapy such as tamoxifen without chemotherapy, there was less than a 2% risk of the cancer spreading to nearby or distant sites and the 5-year overall survival was 98%.
This paper in NEJM reports the results of the Trial Assigning Individualized Options for Treatment (TAILORx), designed to validate the clinical usefulness of Genomic Health’s 21-gene assay called Oncotype DX in women with low-risk, HR-positive, HER2-negative, axillary node—negative invasive breast cancer. Participants were women 18 to 75 years of age who met the National Comprehensive Cancer Network guidelines for the recommendation of adjuvant chemotherapy. They also had to meet the Eastern Cooperative Oncology Group performance-status score of 0 or 1.
Analysis of trial results found that nearly 16% of women had a multigene test score of 10 or lower, while another 68% had a mid-range score of 11 to 25. The rate of invasive disease-free survival in those with a score of 10 or less was 93.8% at 5 years, the rate of freedom from recurrence of breast cancer at a distant or loco-regional site was 98.7%, and rate of overall survival was 98%.
“This should provide a lot of reassurance to women and their physicians,” said Kathy Albain, MD, FACP, FASCO of Loyola University Medical Center and Loyola University Chicago Stritch School of Medicine, a coauthor on the paper. “In women whose breast cancer scored low on the multigene test, there was outstanding survival with endocrine therapy alone. The test provides us with greater certainty of who can safely avoid chemotherapy.”
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More